These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 9184623)

  • 1. Fluvoxamine: a review of the controlled trials in depression.
    Ware MR
    J Clin Psychiatry; 1997; 58 Suppl 5():15-23. PubMed ID: 9184623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacotherapy of depression.
    Joffe RT
    J Psychiatry Neurosci; 1991 Jul; 16(2 Suppl 1):4-9. PubMed ID: 1931936
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of atypical antipsychotics in refractory depression and anxiety.
    Nemeroff CB
    J Clin Psychiatry; 2005; 66 Suppl 8():13-21. PubMed ID: 16336032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Redefining antidepressant efficacy toward long-term recovery.
    Thase ME
    J Clin Psychiatry; 1999; 60 Suppl 6():15-9. PubMed ID: 10235120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between depression severity entry criteria and antidepressant clinical trial outcomes.
    Khan A; Schwartz K; Kolts RL; Ridgway D; Lineberry C
    Biol Psychiatry; 2007 Jul; 62(1):65-71. PubMed ID: 17141744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Placebo response and antidepressant clinical trial outcome.
    Khan A; Detke M; Khan SR; Mallinckrodt C
    J Nerv Ment Dis; 2003 Apr; 191(4):211-8. PubMed ID: 12695731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of depression--newer pharmacotherapies.
    Mulrow CD; Williams JW; Trivedi M; Chiquette E; Aguilar C; Cornell JE; Badgett R; Noël PH; Lawrence V; Lee S; Luther M; Ramirez G; Richardson WS; Stamm K
    Psychopharmacol Bull; 1998; 34(4):409-795. PubMed ID: 10513454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial.
    Spivak B; Strous RD; Shaked G; Shabash E; Kotler M; Weizman A
    J Clin Psychopharmacol; 2006 Apr; 26(2):152-6. PubMed ID: 16633143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluvoxamine: clinical trials and clinical use.
    Freeman CP
    J Psychiatry Neurosci; 1991 Jul; 16(2 Suppl 1):19-25. PubMed ID: 1931932
    [No Abstract]   [Full Text] [Related]  

  • 10. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
    Jahn H; Schick M; Kiefer F; Kellner M; Yassouridis A; Wiedemann K
    Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients.
    Claghorn JL; Earl CQ; Walczak DD; Stoner KA; Wong LF; Kanter D; Houser VP
    J Clin Psychopharmacol; 1996 Apr; 16(2):113-20. PubMed ID: 8690826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrocardiographic findings during extended clinical trials of fluvoxamine in depression: one years experience.
    Hochberg HM; Kanter D; Houser VP
    Pharmacopsychiatry; 1995 Nov; 28(6):253-6. PubMed ID: 8773292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label pilot study of fluvoxamine for mixed anxiety-depression.
    Houck C
    Psychopharmacol Bull; 1998; 34(2):225-7. PubMed ID: 9641005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent studies on selective serotonergic antidepressants: trazodone, fluoxetine, and fluvoxamine.
    Schatzberg AF; Dessain E; O'Neil P; Katz DL; Cole JO
    J Clin Psychopharmacol; 1987 Dec; 7(6 Suppl):44S-49S. PubMed ID: 3123528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mousetrap: managing the placebo effect in antidepressant trials.
    Lakoff A
    Mol Interv; 2002 Apr; 2(2):72-6. PubMed ID: 14993352
    [No Abstract]   [Full Text] [Related]  

  • 16. Notes on the use of fluvoxamine as treatment of depression in HIV-1-infected subjects.
    Grassi B; Gambini O; Scarone S
    Pharmacopsychiatry; 1995 May; 28(3):93-4. PubMed ID: 7568371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM III). A French/Swiss double-blind trial.
    Bougerol T; Uchida C; Gachoud JP; Köhler M; Mikkelsen H
    Psychopharmacology (Berl); 1992; 106 Suppl():S102-8. PubMed ID: 1546121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The status of fluvoxamine among the antidepressive agents].
    Svestka J; Cesková E; Rysánek R; Obrovská V; Kamenická V
    Cesk Psychiatr; 1992 Sep; 88(5):209-19. PubMed ID: 1451197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression.
    Suzuki Y; Fukui N; Sawamura K; Sugai T; Watanabe J; Ono S; Inoue Y; Ozdemir V; Someya T
    J Clin Psychopharmacol; 2008 Jun; 28(3):325-8. PubMed ID: 18480690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials.
    Khan A; Brodhead AE; Kolts RL; Brown WA
    J Psychiatr Res; 2005 Mar; 39(2):145-50. PubMed ID: 15589562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.